Editors Choice Article – Exploration of Ion Channels in Mycobacterium tuberculosis: Implication on Drug Discovery and Potent Drug Targets Against Tuberculosis

Author(s): Manish Dwivedi*.

Journal Name: Current Chemical Biology

Abstract:

Scientific interest in mycobacteria has been sparked by the medical importance of Mycobacterium tuberculosis (Mtb) that is known to cause severe diseases in mammals, i.e. tuberculosis and by properties that distinguish them from other microorganisms which are notoriously difficult to treat. The treatment of their infections is difficult because mycobacteria fortify themselves with a thick impermeable cell envelope. Channel and transporter proteins are among the crucial adaptations of Mycobacterium that facilitate their strength to combat against host immune system and anti-tuberculosis drugs. In previous studies, it was investigated that some of the channel proteins contribute to the overall antibiotic resistance in Mtb. Moreover, in some of the cases, membrane proteins were found responsible for virulence of these pathogens. Given the ability of M. tuberculosis to survive as an intracellular pathogen and its inclination to develop resistance to the prevailing anti-tuberculosis drugs, its treatment requires new approaches and optimization of anti-TB drugs and investigation of new targets are needed for their potential in clinical usage. Therefore, it is imperative to investigate the survival of Mtb. in stressed conditions with different behavior of particular channel/ transporter proteins. Comprehensive understanding of channel proteins and their mechanism will provide us direction to find out preventive measures against the emergence of resistance and reduce the duration of the treatment, eventually leading to plausible eradication of tuberculosis. To read out more, please visit: http://www.eurekaselect.com/180061/article

New Issue | Current Computer-Aided Drug Design; Volume 16 Issue 2

 

ccadd

 

Current Computer-Aided Drug Design aims to publish all the latest developments in drug design based on computational techniques. The field of computer-aided drug design has had extensive impact in the area of drug design.

Current Computer-Aided Drug Design is an essential journal for all medicinal chemists who wish to be kept informed and up-to-date with all the latest and important developments in computer-aided methodologies and their applications in drug discovery. Each issue contains a series of timely, in-depth reviews/mini-reviews, original research articles and letter articles written by leaders in the field, covering a range of computational techniques for drug design, screening, ADME studies, theoretical chemistry; computational chemistry; computer and molecular graphics; molecular modeling; protein engineering; drug design; expert systems; general structure-property relationships; molecular dynamics; chemical database development and usage etc., providing excellent rationales for drug development.

 

Articles from the journal: Current Computer-Aided Drug Design; Volume 16 Issue 2:

 

For details on the articles, please visit this link: http://www.eurekaselect.com/node/582/current-computer-aided-drug-design/issue/16/2727/2/9757

New Issue | CNS & Neurological Disorders – Drug Targets; Volume 18 Issue 10

 

cnsnddt

 

CNS & Neurological Disorders – Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in neurological and central nervous system (CNS) disorders e.g. disease specific proteins, receptors, enzymes, genes.

CNS & Neurological Disorders – Drug Targets publishes guest edited thematic issues written by leaders in the field covering a range of current topics of CNS & neurological drug targets. The journal also accepts for publication original research articles, letters, reviews and drug clinical trial studies.

As the discovery, identification, characterization and validation of novel human drug targets for neurological and CNS drug discovery continues to grow; this journal is essential reading for all pharmaceutical scientists involved in drug discovery and development.

 

Articles from the journal: CNS & Neurological Disorders – Drug Targets; Volume 18 Issue 10

 

 

 

For details on the articles, please visit this link: http://www.eurekaselect.com/node/646/cns-neurological-disorders-drug-targets-/issue/18/2538/10/9564

New Issue | Current Drug Targets; Volume 20 Issue 16

 

cdt-6-1.jpg

 

Current Drug Targets aims to cover the latest and most outstanding developments on the medicinal chemistry and pharmacology of molecular drug targets e.g. disease specific proteins, receptors, enzymes, genes.

Current Drug Targets publishes guest edited thematic issues written by leaders in the field covering a range of current topics of drug targets. The journal also accepts for publication full-length/mini review articles and drug clinical trial studies.

As the discovery, identification, characterization and validation of novel human drug targets for drug discovery continues to grow; this journal is essential reading for all pharmaceutical scientists involved in drug discovery and development.

Articles from the journal: Current Drug Targets; Volume 20 Issue 16

For details on the articles, please visit this link: http://www.eurekaselect.com/node/590/current-drug-targets/issue/20/2521/16/9394

Aims & Scope | Current Computer-Aided Drug Design

 

AIMS & SCOPE

Current Computer-Aided Drug Design aims to publish all the latest developments in drug design based on computational techniques. The field of computer-aided drug design has had extensive impact in the area of drug design.

Current Computer-Aided Drug Design is an essential journal for all medicinal chemists who wish to be kept informed and up-to-date with all the latest and important developments in computer-aided methodologies and their applications in drug discovery. Each issue contains a series of timely, in-depth reviews/mini-reviews, original research articles and letter articles written by leaders in the field, covering a range of computational techniques for drug design, screening, ADME studies, theoretical chemistry; computational chemistry; computer and molecular graphics; molecular modeling; protein engineering; drug design; expert systems; general structure-property relationships; molecular dynamics; chemical database development and usage etc., providing excellent rationales for drug development.

 

ccadd-flyer.jpg

Press Release | Bentham science’s latest book ‘Frontiers in Anti-Cancer Drug Discovery Volume 10’

 

This eBook is authored by Dr. Atta-ur-Rahman, published on June; this book is authored by Atta-ur-Rahman and M. Iqbal Choudhary; published on May 31, 2019. For Further Details, Please Visit : https://ebooks.benthamscience.com/book/9789811400711/

9789811400711-1.jpg

Frontiers in Anti-Cancer Drug Discovery is a book series devoted to publishing the latest advances in anti-cancer drug design and discovery. In each volume, eminent scientists contribute reviews relevant to all areas of rational drug design and drug discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. The book series should prove to be of interest to all pharmaceutical scientists involved in research in anti-cancer drug design and discovery. The book series is essential reading to all scientists involved in drug design and discovery who wish to keep abreast of rapid and important developments in the field. The tenth volume of the series features chapters covering the following topics:

  • Challenges in the Management of Hepatoblastoma
  • The Emerging Role of Monocarboxylate Transporter-1 in Cancer
  • In-vitro Anti-Proliferative Assays and Techniques Used in Pre-Clinical Anti-Cancer Drug Discovery
  • Recent Advances in the Development of Mesoporous Anti-Cancer Drug Nanocarriers
  • Polyphenols and Cancer
  • Glioblastoma Multiforme
  • Cutting Edge Targeting Strategies Utilizing Nanotechnology in Breast Cancer Therapy
Read full press release to find out more at: https://www.eurekalert.org/pub_releases/2019-06/bsp-bsl062019.php

Aims & Scope | Current HIV Research

Aims & Scope

Current HIV Research covers all the latest and outstanding developments of HIV research by publishing original research, review articles and guest edited thematic issues. The novel pioneering work in the basic and clinical fields on all areas of HIV research covers: virus replication and gene expression, HIV assembly, virus-cell interaction, viral pathogenesis, epidemiology and transmission, anti-retroviral therapy and adherence, drug discovery, the latest developments in HIV/AIDS vaccines and animal models, mechanisms and interactions with AIDS related diseases, social and public health issues related to HIV disease, and prevention of viral infection. Periodically, the journal invites guest editors to devote an issue on a particular area of HIV research of great interest that increases our understanding of the virus and its complex interaction with the host.

 

chivr-flyer

 

Read out more at: https://benthamscience.com/journals/current-hiv-research/aims-scope/#top

MOST ACCESSED ARTICLE – Structure, Function, Involvement in Diseases and Targeting of 14-3-3 Proteins: An Update

Author(s): Ylenia Cau, Daniela Valensin, Mattia Mori, Sara Draghi, Maurizio Botta*.

 

Abstract:

14-3-3 is a class of proteins able to interact with a multitude of targets by establishing protein-protein interactions (PPIs). They are usually found in all eukaryotes with a conserved secondary structure and high sequence homology among species. 14-3-3 proteins are involved in many physiological and pathological cellular processes either by triggering or interfering with the activity of specific protein partners. In the last years, the scientific community has collected many evidences on the role played by seven human 14-3-3 isoforms in cancer or neurodegenerative diseases. Indeed, these proteins regulate the molecular mechanisms associated to these diseases by interacting with (i) oncogenic and (ii) pro-apoptotic proteins and (iii) with proteins involved in Parkinson and Alzheimer diseases. The discovery of small molecule modulators of 14-3-3 PPIs could facilitate complete understanding of the physiological role of these proteins, and might offer valuable therapeutic approaches for these critical pathological states.

 

Read more here: http://www.eurekaselect.com/151895

EDITOR’S CHOICE – Macrophage Polarization as a Therapeutic Target in Myocardial Infarction – Current Drug Targets

Journal: Current Drug Targets

Author(s): Yuanyuan Cheng, Jianhui Rong*

Graphical Abstract:

 

Abstract:

Background: Myocardial infarction is characterized by the interruption of blood flow through the heart, directly causing mortality and disability worldwide. Cardiac macrophages exhibit distinct phenotypes (e.g., M1 or M2) and functions (e.g., proinflammatory or anti-inflammatory) in response to the alterations of myocardial microenvironment, and subsequently exacerbate or resolve inflammation in the infarcted hearts. Regulation of macrophage polarization was implicated in myocardial infarction for the quality and outcome of cardiac healing.

Objective: The purpose of this review was to summarise the current understanding on the regulation of macrophage polarization in myocardial infarction and highlight the therapeutic potential of pharmacological regulators in the treatment of myocardial injury via modulating macrophage polarization.

Results: Timely control of M2/M1 ratio by endogenous mediators and pharmacological regulators should help the resolution of inflammation, promote wound healing and prevent cardiac fibrosis after myocardial infarction.

Conclusion: Macrophage polarization deserves better investigations as the therapeutic target for the development of novel drugs against myocardial injury.

Read more here: http://www.eurekaselect.com/156685/article

 

UPCOMING THEMATIC ISSUE – DRUG DISCOVERY AND DEVELOPMENT IN THE MANAGEMENT OF CARDIOMETABOLIC DISEASES – CURRENT DRUG TARGETS

CDT-THEMATIC FLYER-Jun Ren, MD, PhD

https://benthamscience.com/journals/current-drug-targets/

%d bloggers like this: